Overview
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Eligibility
Inclusion Criteria:
- \- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Exclusion Criteria:
- \- Absence of CIDP symptoms
- -History or family history of inherited neuropathy
- -Diagnosed developmental delay or regression
- -History of thrombotic episode
- -Known or suspected hypersensitivity to Privigen
- -Known allergic or other severe reactions to blood products
- -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
- -Pregnant or breastfeeding mother"
